The most clinically relevant mutations described in HCC cells are those of tumor suppressor genes, such as TP53, ARID1/2, telomerase-codifying genes TERT/TERC, as well as alterations of WNT (CTNNB1, AXIN1, AXIN 2) or JAK-STAT signaling pathways (genes such as JAK1, IL6R, IL6ST). This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.